Cover Image
市場調查報告書

組織胺H4受體:開發中產品分析

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359402
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
組織胺H4受體:開發中產品分析 Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 54 Pages
簡介

本報告提供組織胺H4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

組織胺H4受體概要

治療藥的開發

組織胺H4受體:開發中的產品 - 各開發階段

組織胺H4受體:開發中的產品 - 各治療範圍

組織胺H4受體開發中的產品 - 各適應症

組織胺H4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組織胺H4受體:企業開發中的產品

組織胺H4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組織胺H4受體的治療藥開發企業

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • Ziarco Pharma Ltd

組織胺H4受體:藥物簡介

組織胺H4受體:暫停中的計劃

組織胺H4受體:開發中止的產品

組織胺H4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1084TDB

Summary:

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 8 and 1 respectively. Report covers products from therapy areas Immunology, Respiratory, Ear Nose Throat Disorders, Ophthalmology and Dermatology which include indications Allergic Conjunctivitis, Asthma, Cystic Fibrosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Acute Sensorineural Hearing Loss, Atopic Dermatitis, Hearing Disorders, Idiopathic Pulmonary Fibrosis, Inflammation, Rhino-Conjunctivitis, Vertigo, Vestibular Diseases and Vestibular Neuronitis.

The latest report Histamine H4 Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
    • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
    • Griffin Discoveries BV
    • Johnson & Johnson
    • Novartis AG
    • OSE Immunotherapeutics
    • Palau Pharma SA
    • Sensorion SA
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
    • azasetron - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-136 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-48 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-28307474 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-28610244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toreforant tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tritoqualine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UR-63325 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPL-389 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 12, 2017: Sensorion's Oral Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study
      • Aug 22, 2017: Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients
      • Jun 08, 2017: Sensorion Takes a Key Step towards Phase 2 with SENS-401 Thanks to the Positive Results Obtained in the Phase 1 Clinical Trial
      • May 02, 2017: Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model
      • Mar 09, 2017: Sensorion Receives European Authorization to Initiate Phase II Clinical Trial of SENS - 111 to Treat Acute Vertigo
      • Feb 15, 2017: Sensorion Inner Ear Disease Product Candidates and Technology Subject of Multiple Presentations at ARO MidWinter Meeting 2017
      • Feb 15, 2017: Sensorion Presents Poster on its Drug Candidate, SENS-401, at Association for Research in Otolaryngology Annual Meeting
      • Dec 14, 2016: Sensorion provides update on SENS-111 at ARO MidWinter Meeting 2017
      • Dec 14, 2016: Sensorion provides update on SENS-401 at ARO MidWinter Meeting 2017
      • Nov 24, 2016: Sensorion Receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss
      • Nov 17, 2016: Sensorion Presents New Preclinical Results with SENS-401 in Acute Sensorineural Hearing Loss at Neuroscience 2016
      • Oct 17, 2016: Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe
      • Oct 06, 2016: Sensorion presented data from the caloric test with SENS - 111 at the EACPT conference
      • Sep 29, 2016: Sensorion Selects New Drug Candidate, SENS-401, to Treat Vestibular and Auditory Disorders Associated with Inner Ear Lesions
      • Sep 21, 2016: Sensorion Presents Initial Results of Phase 1b Clinical Study on SENS-111 at the AAO-HNSF Annual Meeting in San Diego
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Griffin Discoveries BV, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by OSE Immunotherapeutics, H2 2017
  • Pipeline by Palau Pharma SA, H2 2017
  • Pipeline by Sensorion SA, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top